US Thyroid Research Articles

7435 Thyroid Abscess Post-FNA in an Immunocompetent Host

Abstract Disclosure: B. Gautam: None. M.S. Hossain: None. S. Hossain: None. S.C. Kumar: None. H. liao: None. B. Tiwari: None. D.S. Rosenthal: None. Background: Thyroid Fine Needle Aspiration (FNA) is a common diagnostic procedure for thyroid nodules. Most common post FNA complications are minor pain, bruises and small hematomas. Despite being generally safe, FNA can occasionally lead to rare complications, such as thyroid abscess, especially in immunocompromised individuals. This case highlights the development of a thyroid abscess post-FNA in a 42-year-old immunocompetent female. Case Report: A 42-year-old female presented to ED with painful right sided neck lump. She had undergone FNA of right sided thyroid cyst, 10 days ago without any immediate complications as confirmed on post procedural ultrasonogram. She started having right sided neck pain after FNA which progressively got worse overtime associated with fever, chills and difficulty swallowing without any dyspnea or dysphonia. She denied symptoms of hyperthyroidism or hypothyroidism. Family history was significant for thyroid cancer in her mother and thyroid nodule in a sister. On exam: Temp. 101 F, HR 105 beats/min, BP 113/69 mm Hg, RR 18 breaths/min. Neck exam revealed soft, warm, tender mass in right neck region which was mobile with swallowing without any skin discoloration or discharge. The physical exam was otherwise unremarkable. Laboratory investigations showed elevated WBC 18000 (4.5-11 k/mm3) with absolute neutrophil count 14.4 (1.8-7 k/mm3), normal CMP. Thyroid hormone levels were normal: TSH 0.32 Uiu/ml, FT4 1.0 ng/dl), as were anti-TG ab, TSI and anti-TPO ab. CT scan of Neck with IV contrast showed a 2.8 x 2.5 x 3.8 cm homogeneous right thyroid mass with mass effect on the trachea. US thyroid showed a 3.7 x 2.9 x 3.3 cm right thyroid hypoechoic lesion with increased internal echogenicity and peripheral hyperemia, consistent with a thyroid abscess. Patient underwent IR guided drainage of 30 cc thick, dark brown fluid and started on broad spectrum IV antibiotics which was then modified based on the bacteriology report showing presence of gram-variable rods, specifically Corynebacterium, with significant clinical improvement. Discussion: The thyroid gland is considered resistant to infections because of its characteristics such as encapsulation, high iodine content and rich blood supply. Nevertheless, rarely, patients may develop post FNA complications including bacterial thyroiditis, thyroid abscess and retropharyngeal cellulitis, presenting with acute life-threatening complaints. This case highlights the importance of monitoring for these rare complications along with early diagnosis and treatment which involves drainage and targeted antibiotic therapy. In the presence of suspicious findings on ultrasonogram and a strong family history of thyroid cancer, we also like to emphasize rare cases where a thyroid abscess could originate from necrotizing cancer cell, the likely etiology of thyroid abscess in our patient. Presentation: 6/3/2024

Prevalence and temporal trends of anemia in patients with thyroid disease: 1999–2018 NHANES

BackgroundAnemia and thyroid disease, both prevalent health conditions, often co-occur and may be easily overlooked, collectively imposing a significant burden on society. This study specifically investigated the prevalence and temporal trends of anemia among individuals with thyroid disease in the US population, shedding light on a critical intersection in public health. MethodsUtilizing National Health and Nutrition Examination data from 10 survey cycles (1999–2018), this study included participants aged 20–85 years who self-reported a diagnosis of thyroid disease. Anemia was defined with a cutoff of 12 g/dL for women and 13 g/dL for men. The chi-square test compared prevalence across different categories and survey cycles. Data analysis employed R 4.3.2, with P < 0.05 considered statistically significant. ResultsThe median hemoglobin level among all individuals with thyroid disease was 13.6 g/dL. The overall prevalence of anemia among the US thyroid disease patients was 12.00 % (95 % CI: 10.96–13.09). A noteworthy upward trend in the prevalence of anemia among thyroid disease patients occurred during 1999–2008 (9.58 %, 95 % CI: 8.14–11.18) and 2009–2018 (13.68 %, 95 % CI: 12.26–15.21). Anemia incidence in individuals with thyroid disease was higher in females (9.05 %, 95 % CI: 8.14–10.02), the elderly population (7.98 %, 95 % CI: 7.12–8.91), individuals living alone (5.96 %, 95 % CI: 5.21–6.77), those with high body mass index (5.38 %, 95 % CI: 4.67–6.17), and non-Hispanic Whites (5.33 %, 95 % CI: 4.62–6.11). ConclusionsThe prevalence of anemia in the US population with thyroid disease was 12 %, indicating an increase over the past few decades.

Modeling Thyroid Cancer Epidemiology in the United States Using Papillary Thyroid Carcinoma Microsimulation Model

ObjectivesThyroid cancer incidence increased over 200% from 1992 to 2018, whereas mortality rates had not increased proportionately. The increased incidence has been attributed primarily to the detection of subclinical disease, raising important questions related to thyroid cancer control. We developed the Papillary Thyroid Carcinoma Microsimulation model (PATCAM) to answer them, including the impact of overdiagnosis on thyroid cancer incidence. MethodsPATCAM simulates individuals from age 15 until death in birth cohorts starting from 1975 using 4 inter-related components, including natural history, detection, post-diagnosis, and other-cause mortality. PATCAM was built using high-quality data and calibrated against observed age-, sex-, and stage-specific incidence in the United States as reported by the Surveillance, Epidemiology, and End Results database. PATCAM was validated against US thyroid cancer mortality and 3 active surveillance studies, including the largest and longest running thyroid cancer active surveillance cohort in the world (from Japan) and 2 from the United States. ResultsPATCAM successfully replicated age- and stage-specific papillary thyroid cancers (PTC) incidence and mean tumor size at diagnosis and PTC mortality in the United States between 1975 and 2015. PATCAM accurately predicted the proportion of tumors that grew more than 3 mm and 5 mm in 5 years and 10 years, aligning with the 95% confidence intervals of the reported rates from active surveillance studies in most cases. ConclusionsPATCAM successfully reproduced observed US thyroid cancer incidence and mortality over time and was externally validated. PATCAM can be used to identify factors that influence the detection of subclinical PTCs.

Abstract 13481: A Rare Case of Pembrolizumab (Keytruda®) -Associated Thyrotoxicosis Causing Atrial Dysrhythmias

Introduction: Immune-Check-Point Inhibitors such as pembrolizumab (Keytruda®) are associated with the development of several immune-related adverse events. Case: 70-year-old malewith history of pleomorphic sarcoma of the right lower extremity with metastases to the lungs was started on Pembrolizumab 3 weeks before presenting to the ER with complaints of generalized weakness and palpitations. The patient was tachycardic and EKG showed atrial tachycardia at 144 beats/minute with right bundle branch block (RBBB) ( FIG 1B ). RBBB had been previously noted on EKG ( FIG 1A ). High-sensitivity-troponins were in the range of 29 to 37 ng/l. The TSH on admission was 0.01 mcu/ml with free T4 of 4.7 ng/dl (&gt; twice the upper limit of normal). Of note, TSH was normal prior to the initiation of Pembrolizumab (2.01 ng/dl). Anti-microsomal anti-thyroid peroxidase (TPO) antibodies were also elevated. US thyroid showed heterogeneous thyroid parenchyma concerning for thyroiditis. The patient received multiple doses of IV metoprolol and IV digoxin for rate control before converting spontaneously to normal sinus rhythm, and was then started on metoprolol succinate to maintain the heart rate. Decision Making: Based on the patient’s recent history of initiating Pembrolizumab therapy and normal thyroid function before, his thyroid dysfunction was attributed to the immunotherapeutic agent leading to atrial dysrhythmias. Endocrinology team was consulted, and prednisone 40 mg daily was started. Repeat free T4 after 5 days came down to 2.5 ng/dl. The patient was discharged home on oral Metoprolol and slow prednisone taper in the next few weeks and outpatient follow-up with endocrinology. Conclusion: Thyroid dysfunction is one of the most common immune-related adverse effects of Pembrolizumab that can cause multisystem dysfunction such as dysrhythmias. Therefore, clinicians should be familiar with their unique adverse effects to minimize morbidity and enable appropriate management.

SAT540 A Case of Simultaneous Medullary Thyroid Cancer (MTC) And Papillary Thyroid Cancer (PTC) In a Patient With Germline RET Mutation

Abstract Disclosure: N. Vaghasia: None. G. Jaiswal: None. Introduction: There are only handful of cases reported of concurrent MTC and PTC in a patient with germline RET proto-oncogene mutation. Case: A 41 year old female with no PMH presented to Endocrine clinic for evaluation of recently diagnosed RET mutation. Patient’s nephew passed away at 5 weeks of age from abnormal organogenesis of heart and brain. Genetic testing showed germline RET mutation. Subsequently her brother and his two children was tested positive for RET mutation. Patient underwent genetic testing which was positive for RET mutation. Patient was found to be heterozygous for p.V804M (c.2410G&amp;gt;A) mutation reported as moderate risk mutation in the RET gene. The result was consistent with an increased risk for RET-related cancers. No family history of MTC, pheochromocytoma or primary hyperparathyroidism was identified. Patient was asymptomatic on presentation and no previous symptoms concerning for any RET mutation related disease. Her physical examination was normal. Patient underwent testing for pheochromocytoma and hyperparathyroidism which was unremarkable. Patient’s calcitonin level was also normal. Patient had US thyroid done to evaluate for nodule and was found to have 1.62 x 0.97 x 1.50 cm mixed solid cystic, hypoechoic, irregular margins and punctate echogenic foci right sided nodule. No abnormal cervical lymph nodes. Patient underwent FNA of the suspicious nodule which was reported as benign based on Bethesda classification. Patient’s calcitonin level was undetectable &amp;lt;0.2 pg/ml (0.0-5.0). Patient underwent total thyroidectomy and on surgical pathology had three papillary microcarcinomas, classic type, 0.4 cm (right lobe), 0.3 cm (left lobe) and 0.1 cm (right lobe). Patient had medullary microcarcinoma 0.2 cm on left lobe. Background thyroid with C-cell hyperplasia. No lymphovascular invasion, no extrathyroidal extension and margins cleared. Discussion: Association of simultaneous MTC-PTC have been reported in few case reports in patient with germline RET mutation. There has been no risk factors or specific patient phenotype identified in previous cases to suggest any association between the two. One important feature in our case is the presence of highly suspicious thyroid nodule which on FNA was benign. This raise an important question on whether the co-existence of MTC and PTC in germline RET mutation decreases sensitivity of FNA. Also it is yet unknown if specific mutation like in our case p.V804M (c.2410G&amp;gt;A) is associated with higher incidence of multi-tumor pathology or not. Finally, our patient had normal calcitonin level despite having MTC which is unusual. Conclusion: Coexistence of MTC and PTC in germline RET mutation is an uncommon association and more information is required to understand common features, risk factors, phenotype and cancer aggressiveness in these patients. At this point it cannot be concluded that the association is a mere coincidence. Presentation Date: Saturday, June 17, 2023

The Correlation of Thyroid Hormone Levels and Anti-Thyroidal Drugs on Thyroid Size, Weight, and Ease of Surgical Dissection for Thyroidectomy for Graves' Disease.

Patients with Graves' Disease often have a larger thyroid size than patients without thyroid disease. These patients also have elevated T3 and T4 with decreased TSH. We evaluate whether these thyroid labs, the use of antithyroid agents, or the size of a thyroid on ultrasound, correlate with the pathological size of a thyroid in patients who undergo total thyroidectomy for Graves' Disease. We further determine whether these parameters affect perioperative complications. A retrospective review of patients undergoing total thyroidectomy for Graves' Disease was performed from January 2004 to December 2016 in a single institution. 392 patients were included in the study. Univariate analyses were performed to compare thyroid size on US and pathology as well as weight to preoperative thyroid hormone values and medical comorbidities. Spearman rank correlation and ANOVA were used to identify factors associated with thyroid weight, total pathology size, and differences in size. Multivariate analysis was also performed to evaluate for correlation between thyroid function and perioperative complications. We found that elevated pre-operative T3 levels were associated with larger pathologic size (P = .027) and a greater difference in pathology vs. US thyroid volumes (P = .005), but not increased thyroid weight (P = .286). No significant differences were found for thyroid weight, pathology size, or difference in size for TSH, T4, or any specific preoperative ATD given. Only postoperative calcium levels were found to be statistically significant for TSH < 0.27 (P = .024) for peri-operative complications. These findings may allow for more accurate preoperative planning and intraoperative expectations in patients with Graves' Disease.

A Practical CEUS Thyroid Reporting System for Thyroid Nodules.

Background The role of contrast-enhanced US (CEUS) in reducing unnecessary biopsies of thyroid nodules has received little attention. Purpose To construct and externally validate a thyroid imaging reporting and data system (TI-RADS) based on nonenhanced US and CEUS to stratify the malignancy risk of thyroid nodules. Materials and Methods This retrospective study evaluated 756 patients with 801 thyroid nodules who underwent nonenhanced US, CEUS, and fine-needle aspiration and received a final diagnosis from January 2018 to December 2019. Qualitative US features of the thyroid nodules were analyzed with univariable and multivariable logistic regression to construct a CEUS TI-RADS. The CEUS TI-RADS was validated with use of internal cross-validation and external validation. Results A total of 801 thyroid nodules in 590 female (mean age, 44 years ± 13) and 166 male (mean age, 47 years ± 13 [SD]) patients were included. Independent predictive US features included nodule composition at CEUS, echogenicity, nodule shape, nodule margin, echogenic foci, extrathyroidal extension, enhancement direction, peak intensity, and ring enhancement. The CEUS TI-RADS showed a higher area under the receiver operating characteristic curve of 0.93 (95% CI: 0.92, 0.95; P < .001 in comparison with all other systems), a biopsy yield of malignancy of 66% (157 of 239 nodules), and an unnecessary biopsy rate of 34% (82 of 239 nodules). In the external validation, the area under the receiver operating characteristic curve, biopsy yield of malignancy, and unnecessary biopsy rate of CEUS TI-RADS were 0.89 (95% CI: 0.84, 0.92), 61% (65 of 106 nodules), and 39% (41 of 106 nodules) for the first external validation set and 0.90 (95% CI: 0.85, 0.94), 57% (56 of 99 nodules), and 43% (43 of 99 nodules) for the second external validation set. Conclusion A contrast-enhanced US (CEUS) thyroid imaging reporting and data system was created with thyroid nodule malignancy risk stratification according to the simplified regression coefficients of nonenhanced US and qualitative features of CEUS. Clinical trials registration no. ChiCTR2000028712 Published under a CC BY 4.0 license. Online supplemental material is available for this article.

Ultrasound Characterization of a Solitary Thyroid Nodule According to British Thyroid Association (BTA) - Derived Criteria: A Simple Test of Reliability on a Small Cohort

Abstract Background: US-based thyroid imaging lexicons have been widely used in clinical practice for identification of FNAC-eligible thyroid nodules. A “U”-classification (BTA) was introduced in 2014 with intense researches conducted in last five years trying to test its feasibility and reliability in stratification of US thyroid nodules. Material and Methods: Prospective single-center uni-departmental study aimed at selection of only “solitary” nodules with image-analysis of US features of suspicious and non-suspicious nodules and ascribing each nodule a “U”-class in view of lexicon-provided user-friendly graphic references. Results: A small cohort, of 37 solitary nodules, was selected out of a total of 150 with comparison to FNAC aspiration cytology result according to pathology Bethesda staging. The correlation of each “U” class was compared to pathology (fine needle aspirates) and revealed very good statistical significance. Conclusion: The study suggests that a BTA (The “U”- classification) is a simple reliable test that can be feasibly practiced to select FNAC-eligible nodule amongst multi-nodular glands.

Tuberculous Thyroiditis Post COVID-19 Infection

Thyroid tuberculosis (TT) is a rare disease and can be a diagnostic challenge. Here we highlight a case of TT following COVID-19 infection. A 38-year Myanmar immigrant female presented with nocturnal fever, fatigue, nausea, sore throat, appetite and weight loss for 1 week with dysphagia, neck swelling, dyspnea, and watery diarrhea. Medical history included renal transplant due to ESRD from IgA nephropathy, DM and treated latent TB with no prior or family history of thyroid disease. She had COVID 7 months ago, complicated by allograft rejection. She was tachycardic, febrile but not in acute distress. Neck exam revealed diffuse thyromegaly with tenderness on right lobe without bruit, palpable cervical lymphadenopathy nor tremors. Labs showed WBC 12.8x109/L (4.8-10), and ESR 50 ml/hr (20-40). On admission, she developed AKI and immunosuppressant meds were discontinued. She was started on broad-spectrum antibiotic. CT chest reported moderate loculated right pleural effusion with mid and lower lobe consolidation. Blood and urine culture, pleural fluid, sputum culture for acid-fast bacilli (AFB) and QuantiFERON-TB were negative. Upon persistent fever, RIPE therapy (rifampin, isoniazid, pyrazinamide, ethambutol) was started and stopped after 10 days due to transaminitis and negative TB PCR. Further labs showed TSH 0.04 mIU/ml (0.27-4.2), FT4 2.81 ng/dl (0.93-1.7), TT3 127 ng/dl (80-200), negative TPO and TSI. Endocrinology was consulted for thyroiditis. Ibuprofen and Propranolol were initiated with continuation of prednisone. Repeat thyroid labs normalized in 4 days. US thyroid noted diffuse, heterogenous thyromegaly without hypervascularity or abscess. CT neck showed diffuse thyromegaly 4.2x7.2x7.5 cm in size; right thyroid lobe extended to posterior clavicle with enhanced capsule, without discrete lymph node or vascularity changes, suggestive of thyroiditis. Fine needle aspiration (FNA) of left thyroid lobe drained 3 ml purulent fluid and AFB were seen on direct smear. She was diagnosed as TT, but unable to restart RIPE therapy due to worsening liver function. She expired after cardiac arrest due to intracranial bleeding and brain abscess. Thyroid tuberculosis is a rarely reported clinical entity. This is the first reported case of secondary TB (TT) in post-COVID infected patient from reactivation of latent TB. In our case, follicular destruction caused initial hyperthyroidism with later recovery. It can be difficult to distinguish subacute from suppurative thyroiditis due to TB. Imaging may not always show clear abscess formation. FNA is crucial for diagnosis, and drainage of any abscess. Anti-TB meds can be given, surgery is rarely required. TT should be considered in any immunocompromised patient with fever and neck pain. Imaging should also include evaluation for any CNS spread of TB. Early detection and treatment will help reduce significant morbidity and mortality.

Current approach to surgical management of hyperthyroidism.

Hyperthyroidism is a set of disorders that involve excess synthesis and secretion of thyroid hormones by the thyroid gland, which leads to thyrotoxicosis. The most common forms of hyperthyroidism include diffuse toxic goiter (Graves' disease), toxic multinodular goiter (Plummer disease), and a solitary toxic adenoma. The most reliable screening measure of thyroid function is the thyroid-stimulating hormone (TSH) level. Options for treatment of hyperthyroidism include: antithyroid drugs, radioactive iodine therapy (the preferred treatment of hyperthyroidism among US thyroid specialists), or thyroidectomy. Massive thyroid enlargement with compressive symptoms, a suspicious nodule, Graves' orbitopathy, and patient preference are indications for surgical treatment of thyrotoxicosis. This paper reviews the current literature and controversies on the surgical approach to the management of hyperthyroidism.

Accuracy of Thyroid Imaging Reporting and Data System in Evaluation of Thyroid Neoplasm

Background: Several US Thyroid Imaging Reporting and Data Systems (TIRADS) have been proposed for risk assessment of thyroid nodules. The nodules are usually divided into variant categories based on TIRADS and are then guided to Fine Needle Aspiration (FNA) Biopsy or follow-up, according to the risk of malignancy. Objective: To assess the specificity, sensitivity and accuracy of TIRADS in diagnosis of thyroid neoplasm Patients and Methods: This study included 60 patients presented to the General Surgery and Endocrine Surgery Unite Outpatient Clinic at Mansoura University Hospitals with thyroid disorders. The study was conducted during the period between 1 November 2018 and the end of March 2020. All patients were radiologically evaluated using neck ultrasound with TIRADS classification. Fine needle aspiration was performed and the results of both were compared to the postoperative pathology reports. Results: the current study evaluated the accuracy of TIRADS (TIRADS 3,4a and 4b) compared to (TIRADS 4c and 5) with sensitivity 83.3%, specificity 92.9%, PPV 83.3%, NPV 92.9% and accuracy 90.0%. Conclusion: TIRADS scoring system is of great value in the diagnosis of simple nodular goiter as it gives a degree of accuracy more than 90% compared to FNAC were the degree of accuracy was 78.3%.

Accuracy of Thyroid Imaging Reporting and Data System in Evaluation of Thyroid Neoplasm

Background: Several US Thyroid Imaging Reporting and Data Systems (TIRADS) have been proposed for risk assessment of thyroid nodules. The nodules are usually divided into variant categories based on TIRADS and are then guided to Fine Needle Aspiration (FNA) Biopsy or follow-up, according to the risk of malignancy. Objective: To assess the specificity, sensitivity and accuracy of TIRADS in diagnosis of thyroid neoplasm Patients and Methods: This study included 60 patients presented to the General Surgery and Endocrine Surgery Unite Outpatient Clinic at Mansoura University Hospitals with thyroid disorders. The study was conducted during the period between 1 November 2018 and the end of March 2020. All patients were radiologically evaluated using neck ultrasound with TIRADS classification. Fine needle aspiration was performed and the results of both were compared to the postoperative pathology reports. Results: the current study evaluated the accuracy of TIRADS (TIRADS 3,4a and 4b) compared to (TIRADS 4c and 5) with sensitivity 83.3%, specificity 92.9%, PPV 83.3%, NPV 92.9% and accuracy 90.0%. Conclusion: TIRADS scoring system is of great value in the diagnosis of simple nodular goiter as it gives a degree of accuracy more than 90% compared to FNAC were the degree of accuracy was 78.3%.

SAT-478 A Case of Congenital Thyroid Hemi-Agenesis- Caution for Complications!

Introduction: Congenital Thyroid hemi-agenesis is an uncommon clinical entity. We present a case highlighting the importance of awareness of this condition and the need to evaluate and manage co-existing hypothyroidism and risk of malignancy. Case: A 20 year old female known to have Hashimoto’s thyroiditis (non-adherent to levothyroxine), and hemi-agenesis of left lobe of thyroid gland, presented with right-sided thyroid enlargement. She was clinically euthyroid. Physical exam: enlarged right sided thyroid gland with palpable anterior cervical lymphadenopathy. Left lobe could not be palpated. TFTs were notable for TSH 4.98 uIU/ml (0.358-3.74) and Free T4 0.79 ng/dl (0.76-1.46) consistent with sub-clinical hypothyroidism while Anti TPO antibody was positive at 8332.8 U/mL (0 - 60). CBC negative for leukocytosis. US thyroid: left-sided thyroid agenesis with intact isthmus and enlargement of right lobe of the thyroid 7.7 cm x 1.6 cm x 2.6 cm with 2 sub-centimeter hypoechoic solid nodules and 2 enlarged lymph nodes 1.5 cm and 2.3 cm (not found in US thyroid 2 years ago) Levothyroxine was re-started. ENT evaluation determined that her lymphadenopathy was benign and consistent with Hashimoto’s thyroiditis. Subsequent TFTs improved. Discussion: Thyroid Gland embryogenesis occurs in the 4th week of fetal life. Subsequent abnormal bilobal differentiation of the thyroid gland is presumed to be the etiology of congenital hemi-agenesis. Its prevalence in several studies is estimated to be between 0.05-0.25%. It is symptomatic pre-dominantly in females and may have familial origin with vast majority of cases having left hemi-agenesis with intact isthmus. It is helpful to know that most symptomatic patients have compensatory hypertrophy of the remnant lobe. It is important to remember that compensatory enlargement of the remnant lobe in the setting of hypothyroidism may be a sign of insufficient endogenous thyroxine production and/or replacement. Although rarely symptomatic, hemi-thyroid remnant may need to be evaluated for co-existing hyperthyroidism, hypothyroidism, carcinoma and multinodular goiter among others, with hypothyroidism thought to be the most common. US thyroid is a useful modality to help guide the evaluation of patients with hemi-agenesis. Awareness of this congenital condition is key in preventing unnecessary evaluations and interventions. Non-resolving lymphadenopathy in Hashimoto’s thyroiditis must be evaluated for lymphoma, however, based on studies, no additional risk of malignancy was identified in patients with underlying thyroid hemi-agenesis.

Diagnosing Graves’ Disease and Non-Graves Hyperthyroidism Using TSH Receptor Antibody Test versus Non-TSH Receptor Antibody Test Methods of Diagnosis

Background: Differentiating Graves hyperthyroidism from the other causes of hyperthyroidism, using serum TRAb testing is essential step for diagnosis. Objectives: To study importance of TRAb in the diagnosis of Graves’ disease, distinguishing it from thyroiditis, and comparing it with clinical features and other tests such as TPOAb, US thyroid and thyroid scintiscan. Methods: A cross-sectional study was conducted on 120 patients attending endocrine clinicErbil city. Patients were studied on clinical feature basis and investigated with serum TRAb, TPOAb, TSH, Free T4, and Ultrasound examination of thyroid gland. Fisher exact test and Chi Square test of independence, Correlation coefficient and t-test of independence were used. Results: Fifty-two patients were found to have Graves’ disease; There was significant correlation between TRAb positivity and diagnosis of Graves’ disease p 0.05. Conclusion: A positive correlation was found between TRAb titer and positivity and no significant relation between TPOAb levels between Graves’ disease patients compared with thyroiditis patients, respectively.

Patient Eligibility for Transoral Endocrine Surgery Procedures in the United States

Transoral endocrine surgery (TES) allows thyroid and parathyroid operations to be performed without leaving any visible scar on the body. Controversy regarding the value of TES remains, in part owing to the common belief that TES is only applicable to a small, select group of patients. Knowledge of the overall applicability of these procedures is essential to understand the operation, as well as to decide the amount of effort and resources that should be allocated to further study the safety, efficacy, and value of these operations. To determine what percentage of US patients undergoing thyroid and parathyroid surgery are eligible for TES using currently accepted exclusion criteria. Cross-sectional study of 1000 consecutive thyroid and parathyroid operations (with or without neck dissection) performed between July 1, 2015, and July 1, 2018, at 3 high-volume academic US thyroid- and parathyroid-focused surgical practices (2 general surgery, 1 otolaryngology-head and neck endocrine surgery). Eligibility for TES was determined by retrospectively applying previously published exclusion criteria to the cases. The primary outcome was the percentage of thyroid and parathyroid cases eligible for TES. Secondary outcomes were a subgroup analysis of the percentage of specific types of cases eligible and the reasons for ineligibility. The mean (SD) age of the 1000 surgical patients was 53 (15) years, mean (SD) body mass index (calculated as weight in kilograms divided by height in meters squared) was 29 (7), and 747 (75.0%) of the patients were women. Five hundred fifty-eight (55.8%) of the patients were eligible for TES. Most patients with thyroid nodules with cytologically indeterminate behavior (165 of 217 [76.0%]), benign thyroid conditions (166 of 240 [69.2%]), and primary hyperparathyroidism (158 of 273 [57.9%]) were eligible for TES, but only 67 of 231 (29.0%) of patients with thyroid cancer were eligible. Among all 1000 cases reviewed, previous neck operation (97 of 441 [22.0%]), nonlocalized primary hyperparathyroidism (78 of 441 [17.7%]), and need for neck dissection (66 of 441 [15.0%]) were the most common reasons for ineligibility. More than half of all patients undergoing thyroid and parathyroid surgery in this study were eligible for TES. This broad applicability suggests that a prospective multicenter trial is reasonable to definitively study the safety, outcomes, and cost of TES.

Diagnostic Accuracy of Real-Time Sonography in Differentiating Diffuse Thyroid Disease From Normal Thyroid Parenchyma: A Multicenter Study.

The purpose of this multicenter study was to assess the diagnostic accuracy of real-time sonography (US) for differentiating diffuse thyroid disease (DTD) from normal thyroid parenchyma among radiologists blinded to patients' clinical, serologic, and imaging history and to determine the differences in diagnostic accuracy among radiologists from different institutions. From January to March 2017, 214 patients underwent preoperative thyroid US and subsequent thyroid surgery at four participating institutions. Real-time US was performed at each institution by an attending radiologist, who classified US diagnoses into one of the following four categories based on US findings: no DTD, indeterminate, suspicious for DTD, and DTD. The outcomes of US diagnoses were compared with histopathologic results to determine the diagnostic accuracy of real-time US at each institution. Histopathologic results included normal thyroid parenchyma (n = 143), Hashimoto thyroiditis (n = 29), non-Hashimoto lymphocytic thyroiditis (n = 37), and diffuse hyperplasia (n = 5). Normal thyroid parenchyma and DTD exhibited statistically significant differences in echogenicity, echotexture, size, glandular margin, vascularity of thyroid, and US classification. There was positive correlation between US classification and histopathologic results at all institutions for detecting DTD. The highest diagnostic indexes were obtained when the cutoff criterion was suspicious for DTD. There was favorable diagnostic accuracy, with statistically significant differences, at all institutions for the diagnosis of DTD. Real-time US can be helpful for differentiating DTD from normal thyroid parenchyma.

Demographic and Clinical Features of Thyroid Carcinomas in Republic of Macedonia (1999-2010).

BACKGROUND:Thyroid carcinomas (TC) are the most common endocrine malignancies. In some parts of the world, the incidence of TCs has increased over the past few decades, especially in females according to some studies.AIM:We have set as the objective for our study to analyse the demographic, ultrasound features, thyroid hormonal status and frequency of thyroid carcinomas in the Republic of Macedonia according to histopathological type.MATERIALS AND METHODS:Retrospective analysis of medical data from all diagnosed and treated patients with TC at the Institute of Pathophysiology and Nuclear Medicine for the period 1999-2010 was performed. Demographic characteristics: age at diagnosis, gender, histopathological type of TC and from clinical features: US findings and thyroid hormonal state at initial examination and their distribution in eight state regions were evaluated.RESULTS:Total number of 204 patients with TC in the Republic of Macedonia was registered. Papillary thyroid carcinoma (PTC) was the most frequent with 131 pts (64.21%), follicular (FTC) with 13 pts (6.37%) was second thyroid malignoma, followed by medullary (MTC) with 12 pts (5.88%), anaplastic (ATC) 11 pts (5.39%) and the rarest types were Hurtle cell carcinoma and intrathyroid sarcoma with only 1 diagnosed case. Age varied widely from 7 yrs to 88 yrs age (average 47.9 ± 16.6 yrs). PTC was more prevalent in younger age groups, while ATC was diagnosed in elderly patients. In all of the eight-country regions, the prevalence rate was higher for females than males (3:1) or 15.21/105 female to 5.03/105 male prevalence rate. According to US appearance mostly TC was unilateral in 42.65% and multifocal in 7.84% with dimensions from 15 to 50 mm.CONCLUSION:There is an increase in incidence and prevalence rate of TCs in our country, mostly PTC, while reduction exists in the number of diagnosed cases of ATC and FTC, comparing with previous studies before iodine prophylaxis program. Different from described in the literature is female: male (4:1) ratio for ATC. According to US features, we can conclude that introduction of more detailed reporting system may improve diagnostic accuracy.

Do US thyroid cancer incidence rates increase with socioeconomic status among people with health insurance? An observational study using SEER population-based data

ObjectivesThe US thyroid cancer incidence rates are rising while mortality remains stable. Trends are driven by papillary thyroid cancer (PTC), the predominant cancer subtype which has a very good prognosis....

Central Neck Dissection in the Treatment of Well-Differentiated Thyroid Cancer

Therapeutic central compartment neck dissection (CCND) is required for confirmed nodal metastasis in patients with differentiated thyroid cancer. The need for routine prophylactic CCND in patients with papillary thyroid cancer is controversial. This article presents the current evidence to inform the debate against the background of the recommendations of US and British thyroid cancer guidelines. Potential advantages of pCCND include reduced local recurrence, preventing the need for further central compartment surgery and improved staging. Opponents claim that there is no proven patient benefit and that there is increased risk of recurrent laryngeal nerve injury and hypocalcemia.

Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates.

Survival rates are commonly used to measure success in treating cancer, but can be misleading. Modern diagnostic practices can lead to the appearance of improving cancer survival, as tumors are diagnosed earlier (lead-time bias) or as an increasing proportion are slow-growing (length bias), whereas the actual burden of cancer deaths is unchanged. Increasingly, more subclinical thyroid cancers are being diagnosed. The objective of the current study was to determine whether thyroid cancer survival rates have been affected by this phenomenon. The authors analyzed survival data from patients with thyroid cancer who were treated at Memorial Sloan Kettering Cancer Center (MSKCC) from 1950 to 2005, and United States population-based incidence, prevalence, and survival data from 1973 to 2009 in the Surveillance, Epidemiology, and End Results data set. US thyroid cancer incidence has increased 3-fold from 1975 to 2009. Over time, the proportion of thyroid cancers that are subcentimeter in size has increased from 23% (1983) to 36% (2009). At MSKCC, this percentage rose from 20% (1950) to 35% (2005). The incidence rates of large tumors (>6 cm) and distant metastasis have not changed. In the United States, 10-year relative survival improved from 95.4% to 98.6% (1983-1999). At MSKCC, 10-year disease-specific survival improved from 91.1% to 96.1% (1950-2005). However, when stratified by tumor size and stage, no changes in survival outcomes were observed. US thyroid cancer mortality rates have remained stable (1975-2009). Modern medical practices increasingly uncover small, asymptomatic thyroid cancers. Survival rates appear improved, but this finding is spurious, attributable instead to shifts in the characteristics of disease being diagnosed. Relying on survival rates to measure success in treating thyroid cancer may reinforce inappropriately aggressive management. Treatment decisions in thyroid cancer should be made based on mortality, not survival data.